Intelligent Liver Function Test (iLFT) and Primary Biliary Cholangitis (PBC) | GileadPro

John Dillon is Professor of Hepatology and Gastroenterology in the Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, based at Ninewells Hospital, Dundee. He is an Honorary Consultant with NHS Tayside, leading a busy general hepatology service and a research group, a former President of the Scottish Society of Gastroenterology, and until recently Vice President for Hepatology of the British Society of Gastroenterology.

His award-winning research interests include new pathways of care for patients with abnormal liver function tests (LFTs) for people infected with HCV as well as novel diagnostics and treatments for metabolic dysfunction-associated steatotic liver disease (MASLD). He has published over 200 peer reviewed original research papers.

The impact of his research work includes the Tayside region of Scotland reaching WHO HCV elimination targets in 2020 and the deployment of iLFT into routine NHS care. He chairs the Scottish HCV Action Plan Clinical Leads Group and is a member of the Scottish Government’s Ministerial advisory board for Blood Borne Viruses and Sexual Health. He previously twice led the development group of the UK consensus guidelines for HCV and has chaired the Hepatitis C SIGN guideline development group and its revisions.

Dr Ruairi Lynch is a consultant Hepatologist and NHS Research Scotland fellow based in Ninewells Hospital and Medical School, Dundee. He is also a clinical lecturer at the University of Dundee and established and leads the Scottish Autoimmune Liver Group.

Dr Lynch completed his training in Edinburgh from 2014 to 2021 as a clinical lecturer and honorary Gastroenterology registrar on the prestigious Wellcome Trust funded Edinburgh Clinical Academic Track. His PhD research focused on modulating the mononuclear response following acute liver injury. Dr Lynch’s current research interest is in primary biliary cholangitis and the identification and diagnosis of liver disease. He was recently lead on the NIHR funded Scottish Hepatology Access Research Partnership which focused on improving access to liver services for patients in socially and geographically isolated populations in Scotland.